249 related articles for article (PubMed ID: 9759608)
1. Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators.
Lügering N; Kucharzik T; Stoll R; Domschke W
Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):338-44. PubMed ID: 9759608
[TBL] [Abstract][Full Text] [Related]
2. [A system of nonspecific defense in chronic inflammatory bowel diseases--pathophysiologic and therapeutic aspects].
Lügering N; Kucharzik T; Stoll R; Domschke W
Z Gastroenterol; 1998 Feb; 36(2):173-87. PubMed ID: 9544501
[TBL] [Abstract][Full Text] [Related]
3. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
Amati L; Caradonna L; Jirillo E; Caccavo D
Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
5. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.
Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R
J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068
[TBL] [Abstract][Full Text] [Related]
6. The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions.
Bhardwaj RS; Zotz C; Zwadlo-Klarwasser G; Roth J; Goebeler M; Mahnke K; Falk M; Meinardus-Hager G; Sorg C
Eur J Immunol; 1992 Jul; 22(7):1891-7. PubMed ID: 1378023
[TBL] [Abstract][Full Text] [Related]
7. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
8. [Significance of intestinal inflammation in the pathogenesis of spondylarthropathies].
Mielants H; Veys EM
Verh K Acad Geneeskd Belg; 1996; 58(2):93-116. PubMed ID: 8768479
[TBL] [Abstract][Full Text] [Related]
9. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production.
Liu Z; Colpaert S; D'Haens GR; Kasran A; de Boer M; Rutgeerts P; Geboes K; Ceuppens JL
J Immunol; 1999 Oct; 163(7):4049-57. PubMed ID: 10491009
[TBL] [Abstract][Full Text] [Related]
10. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells.
Panja A; Goldberg S; Eckmann L; Krishen P; Mayer L
J Immunol; 1998 Oct; 161(7):3675-84. PubMed ID: 9759892
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E10 antigen) in Crohn's disease.
Schmid KW; Lügering N; Stoll R; Brinkbäumer P; Winde G; Domschke W; Böcker W; Sorg C
Hum Pathol; 1995 Mar; 26(3):334-7. PubMed ID: 7890287
[TBL] [Abstract][Full Text] [Related]
12. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.
Agius LM
J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone in inflammatory bowel disease.
De Pascalis B; Bianchi A; Satta MA; Lupascu A; Mentella MC; Leo D; Fiore F; Fedeli P; Pontecorvi A; Pola P; Melina D; Gasbarrini A; De Marinis L; Armuzzi A
Eur Rev Med Pharmacol Sci; 2006; 10(1):13-6. PubMed ID: 16494105
[TBL] [Abstract][Full Text] [Related]
14. Activated macrophage-like THP-1 cells modulate anulus fibrosus cell production of inflammatory mediators in response to cytokines.
Kim JH; Studer RK; Sowa GA; Vo NV; Kang JD
Spine (Phila Pa 1976); 2008 Oct; 33(21):2253-9. PubMed ID: 18784630
[TBL] [Abstract][Full Text] [Related]
15. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.
Caradonna L; Amati L; Magrone T; Pellegrino NM; Jirillo E; Caccavo D
J Endotoxin Res; 2000; 6(3):205-14. PubMed ID: 11052175
[TBL] [Abstract][Full Text] [Related]
16. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of inflammatory bowel disease in a mouse model of depression.
Ghia JE; Blennerhassett P; Deng Y; Verdu EF; Khan WI; Collins SM
Gastroenterology; 2009 Jun; 136(7):2280-2288.e1-4. PubMed ID: 19272381
[TBL] [Abstract][Full Text] [Related]
18. Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis.
Frosch M; Vogl T; Waldherr R; Sorg C; Sunderkötter C; Roth J
J Leukoc Biol; 2004 Feb; 75(2):198-206. PubMed ID: 14597726
[TBL] [Abstract][Full Text] [Related]
19. Importance of combined treatment with IL-10 and IL-4, but not IL-13, for inhibition of monocyte release of the Ca(2+)-binding protein MRP8/14.
Lügering N; Kucharzik T; Lügering A; Winde G; Sorg C; Domschke W; Stoll R
Immunology; 1997 May; 91(1):130-4. PubMed ID: 9203976
[TBL] [Abstract][Full Text] [Related]
20. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
